A double‐blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients

Guillibert, E.; Pélicier, Y; Archambault, Joanne; Chabannes, J.; Clerc, G.; Desvilles, M; Guibert, Marc; Pagot, R.; Poisat, J. L.; Thobie, Y

doi:10.1111/j.1600-0447.1989.tb07192.x

Cited by 73 publications

(29 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies of SSRIs including non-TCA comparators (e.g., trazodone, mianserin, monoamine oxidase inhibitors) were excluded from meta-analysis. Letters to authors were also sent out requesting information on missing data; this approach yielded additional information on two studies (Guillibert et al, 1989;Judd et al, 1993). We were able to identify 36 random double-blind studies of TCAs and SSRIs in major depression as defined by DSM-III or DSM-III-R (see Tables 1-3).…”

Section: Methodsmentioning

confidence: 99%

Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis

1997

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis

1997

View full text Add to dashboard Cite

“…Paroxetine was as effective as clomipramine in a 6-week, double-blind, randomized trial of 79 elderly depressed outpatients (Guillibert et al, 1989). At study entry, mean HAM-D scores were 27.9 for the paroxetine group and 27.5 for the clomipramine group.…”

Section: Ssris Vs Tcasmentioning

confidence: 99%

Treatment of severe depression with the selective serotonin reuptake inhibitors

Schatzberg

1996

Depress. Anxiety

View full text Add to dashboard Cite

The selective serotonin reuptake inhibitors (SSRIs) are recognized as effective as and better tolerated than older antidepressant therapies and have become the drugs of choice in the treatment of mild to moderate depression. However, there is a clinical impression that the SSRIs are less effective than older therapies in the severely depressed patient. A limited number of trials have attempted to address this issue. This review assesses 16 controlled studies of SSRIs in severe depression. The findings from a majority of studies found the SSRIs to be superior to placebo and as effective as but better tolerated than the tricyclic antidepressants (TCAs) in severely depressed patients. Although future studies are needed to corroborate and elaborate on these data, studies still support the use of SSRIs in this patient population. Depression and Anxiety 4:182–189, 1996/1997. © 1997 Wiley‐Liss, Inc.

show abstract

“…55 years (range 55 to 80) for bupropion (Branconnier et al, 1983;Kane et al, 1983) and mirtazapine (Halikas, 1985), and ! 60 years (range 60 to 85) for paroxetine (Guillibert et al, 1989;Lundmark et al, 1989). Other clinical trials conducted on elderly subjects were on fluoxetine, range 61 to 90 years (Feighner and Cohn, 1985) and sertraline, range 63 to 85 years (Cohn et al, 1990).…”

mentioning

confidence: 98%